Efficacy and Safety of Osimertinib for HK Chinese with Metastatic T790M Mutated NSCLC-real world setting.

Trial Identifier:	D5160R00020
Sponsor:	AstraZeneca
NCTID::	NCT03219970
Start Date:	September 2017
Primary Completion Date:	October 2020
Study Completion Date:	October 2020
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Hong Kong, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.